Maplight Therapeutics, Inc. · NASDAQ:MPLT
Maplight Therapeutics — Technical Presentation (July 2026)
27 slides from Maplight Therapeutics's technical presentation, Jul 27, 2026
Slide 1: Topline Data from Phase 2 ZEPHYR Trial Evaluating ML-007C-MA in Schizophrenia
Exhibit 99.1 Topline Data from Phase 2 ZEPHYR Trial Evaluating ML-007C-MA in Schizophrenia July 27, 2026
Slide 2: Safe Harbor and Forward-Looking Statements
Safe Harbor and Forward-Looking Statements This presentation and any accompanying oral commentary have been prepared by MapLight Therapeutics, Inc. (“MapLight”, “we,” “us,” “our,” the “Company”, or similar terms) for informational purposes only and not for any other purpose. This presentation contai
Slide 3: Agenda
Agenda Executive Summary and Chris Kroeger, M.D. Co-Founder and Chief Executive Officer Unmet Medical Need Phase 2 ZEPHYR Erin Foff, M.D., Ph.D. Chief Medical Officer Design and Results Future Development Chris Kroeger, M.D. Co-Founder and Chief Executive Officer Considerations Closing Remarks Chris
Slide 4: ZEPHYR Met Its Primary Endpoint, Supporting Advancement into Confirmatory Pivotal Study
ZEPHYR Met Its Primary Endpoint, Supporting Advancement into an Additional, Confirmatory Pivotal Study • ZEPHYR met its primary endpoint and demonstrated a substantial treatment effect, supported by concordant improvements across key secondary efficacy measures • Robust and clinically meaningful imp
Slide 5: Unmet Need in Schizophrenia Remains High
Unmet Need in Schizophrenia Remains High Affects Over 20 Million People Globally, Including More Than 3 Million in the U.S. Patients Remain Underserved by Current SOC ~70% ~30% ~40-50% Antipsychotics… discontinue oral therapies within 18 show no meaningful experience an inadequate months, often due
Slide 6: Developing a Differentiated Treatment, Designed to Translate into Real-World Use
Developing a Differentiated Treatment, Designed to Translate into Real-World Use 210/3 mg BID delivered statistically significant improvement across complementary measures of schizophrenia symptoms • PANSS Total Score (mITT, primary endpoint): Effect Size of 0.37 (-4.5 pts versus placebo, p=0.015) •
Slide 7: Phase 2 ZEPHYR Design and Results
Phase 2 Design and Results Erin Foff, M.D., Ph.D. | Chief Medical Officer
Slide 8: ZEPHYR Study Outline
ZEPHYR Study Outline Designed and Sized to Serve as a Registrational Study Blinded Treatment Period Screening Follow-up (Day 1 to 35) Period Period (Day -7 to -1) (Day 36 to 42) Week 1 Week 2 Week 3 Week 4 Week 5 Primary Endpoint Placebo Ÿ (N=104) • N = 307 (1) • Randomized 1:1:1 ML-007C-MA Ÿ 210/3
Slide 9: Demographics & Baseline Characteristics
Demographics & Baseline Characteristics Placebo 210/3 mg BID 330/6 mg QD (1) N = 104 N = 99 N = 102 Demographics Mean Age, years 40 42 40 Male Sex at Birth, n (%) 80 (77%) 69 (70%) 77 (75%) Race, n (%) Black or African American 81 (78%) 73 (74%) 80 (78%) White 17 (16%) 22 (22%) 16 (16%) Other 6 (6%)
Slide 10: Primary Endpoint: PANSS Total Score
Primary Endpoint: PANSS Total Score 210/3 mg BID Met Primary Endpoint Change From Baseline in PANSS Total Score (LS Mean Difference) 210/3 mg 330/6 mg 0 Placebo BID QD -2 N N=103 N=93 N=98 -4 LS Mean CFB -7.2 -11.7 -10.0 -6 LS Mean Diff -4.5 -2.8 vs. Placebo -8 P-value p=0.015 p=0.110 * -10 Effect S
Slide 11: Primary Endpoint: PANSS Total Score Completer Analysis
Primary Endpoint: PANSS Total Score Robust Effect Demonstrated in Prespecified Completer Analysis Change From Baseline in PANSS Total Score (LS Mean Difference) Placebo 210/3 mg BID 0 (Completers) (Completers) -2 N N=88 N=73 -4 LS Mean CFB -7.5 -13.4 -6 LS Mean Diff -6.0 -8 vs. Placebo * P-value p=0
Slide 12: Key Secondary Endpoint: CGI-S
Key Secondary Endpoint: CGI-S Significant Improvement Corroborates PANSS Improvement Change From Baseline in CGI-S (LS Mean Difference) 0 -0.1 • Clinically meaningful and statistically -0.2 significant improvement in CGI-S vs. placebo at Week 5 -0.3 – 0.38-point improvement -0.4 -0.5 – -0.75 active
Slide 13: PANSS Positive Symptoms
PANSS Positive Symptoms Significant Improvement in PANSS Positive Marder Factor and Positive Subscale Change From Baseline in PANSS Positive Symptoms (LS Mean Difference) 0 PANSS + PANSS + Placebo Marder Subscale -0.5 -1 N 103 93 93 -1.5 -1.9/-1.9 LS Mean * (Marder/ -3.4 -4.2 -2 CFB Subscale) -2.5 L
Slide 14: Secondary Endpoint: Cognitive Composite
Secondary Endpoint: Cognitive Composite Robust and Clinically Meaningful Improvement on Cognitive Performance Pre-specified Cognitive Composite Score Results No observed significant relationship between cognitive improvement and PANSS change Cognitive Composite Score Placebo: r=-0.071, p=0.678; BID:
Slide 15: Implications of Cognitive Signal Beyond ZEPHYR
Implications of Cognitive Signal Beyond ZEPHYR Supports Rationale for VISTA and Broader Development The Signal Supports the Underlying Biology Cognitive Impairment Remains an Unmet Need • Cognitive impairment is estimated to affect >80% of patients with • The cognitive benefit was observed on a pres
Slide 16: Demonstrated Effect Across Multiple Endpoints and Symptom Domains
210/3 mg BID Demonstrated Effect Across Multiple Endpoints and Symptom Domains N LS Mean Difference [95% CI] Effect Size P-value Active / PBO ← ML-007C-MA favored PBO favored → PANSS Total Score – mITT 93 / 103 0.37 0.015 -10 -8 -6 -4 -2 0 PANSS Total Score - Completers 73 / 88 0.50 0.002 -10 -8 -6
Slide 17: ML-007C-MA Was Generally Well Tolerated
ML-007C-MA Was Generally Well Tolerated • Adverse events, primarily cholinergic in nature, were mostly mild Adverse Events (1) • No serious or drug-related severe TEAEs occurred with either dose Mostly Mild • The only severe TEAE (pneumonia) was assessed as unrelated to study drug • There were no in
Slide 18: Most Adverse Events Were Mild
Most Adverse Events Were Mild All Cause Discontinuation Was Low at 19.9% Across Active Treatment Arms Rates of TEAEs With BID Dosing GI TEAEs ≥2% in Active Arm and > Placebo Placebo 210/3 mg BID Placebo 210/3 mg BID N=104 N = 99 N=104 N = 99 Discontinuations Mild Moderate Mild Moderate Nausea 6% 0 2
Slide 19: Rates of TEAEs for Cobenfy in Pivotal Studies
Rates of TEAEs for Cobenfy in Pivotal Studies (1) All Cause Discontinuation Ranged From 25.4%-36.8% at 5 weeks EMERGENT-2 EMERGENT-3 GI TEAEs >2% in Active Arm and > Placebo Cobenfy FDA Label Placebo Active Placebo Active Placebo Active EMERGENT-2/3 Pooled Discontinuations (N=253) (N=251) (2) (2) (3
Slide 20: Future Development Considerations
Future Development Considerations Chris Kroeger, M.D. | Co-Founder and Chief Executive Officer
Slide 21: Significant Opportunity for New Therapies
Significant Opportunity for New Therapies 210/3 mg BID Effect Size Falls Within the Range of Approved Antipsychotics PANSS Total Score: Standardized Effect Sizes (Cohen’s d) Peak Sales $5.0B $3.2B $3.4B $5.8B $6.2B $2.0B $4.3B $6.0B $2.6B (1) (Year) (2010) (2036E) (2007) (2011) (2013) (2020) (2028E)
Slide 22: ML-007C-MA Target Product Profile Has Potential to be Differentiated
ML-007C-MA Target Product Profile has Potential to be Differentiated Across Multiple Dimensions In development (2) (3) (4) (1) Cobenfy Emraclidine Direclidine SOC ML-007C-MA Program Antipsychotics M /M Agonist + M PAM M Agonist 1 4 4 4 M /M Agonist + 1 4 Mechanism of Action Peripheral Antagonist Per
Slide 23: Phase 3 Program and Path to NDA Submission
Phase 3 Program and Path to NDA Submission Confirmatory Pivotal Trial Expected to Support Initial Approval (1) (1) ZEPHYR-2 (Study 311) ZEPHYR-3 (Study 312) ZEPHYR-1 (Study 211) Engage with the FDA Planned Planned at EOP2 Meeting Complete • Similar design to Phase 2, evaluating • Additional pivotal
Slide 24: Closing Remarks
Closing Remarks Chris Kroeger, M.D. | Co-Founder and Chief Executive Officer
Slide 25: Closing Remarks
Closing Remarks Statistically Significant Across Potentially Differentiating Tolerability Built for Complementary Measures Cognitive Signal Real-World Use • Met the primary endpoint on PANSS Total • Prespecified Cognitive Composite Score • No serious or drug-related severe adverse Score (ES=0.37), w
Slide 26: Advancing a Broad and Diversified Pipeline
Advancing a Broad and Diversified Pipeline Program Circuit Indications Preclinical Phase 1 Phase 2 Phase 3 Anticipated Milestones Engage with FDA at Schizophrenia ZEPHYR EOP2 meeting ML-007C-MA Potential in Direct and Indirect other indications M /M agonist 1 4 Pathways being explored co-formulated
Slide 27: Q&A
“o Qs MapLight Q&A
MapLight Therapeutics — Technical Presentation (July 2026) on 6ix